Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesInduction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsAntibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity.A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody responseConcordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression systemMechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HThe role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationImpact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interactionIdentification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates.
P2860
Q24561905-DC0086A3-E09B-4C51-9EA1-B8974C4FF808Q30401836-34AD9925-9BA0-446A-AFBE-11A3B513050AQ33205911-5D961A21-E318-41A4-AF1C-0E5A4BAB3F96Q33313394-A2791C86-9960-4D42-95E4-83087455FB7DQ33719511-DCEEAC51-E4A1-4A85-93B3-9AF89560E076Q33737723-A98DBDE0-5D49-47E4-AAF9-50D8A1304130Q33781344-875E4A79-2CF1-46EC-A76B-51DCA689A2E3Q33803590-F5C9D2B9-625B-4BAC-83C3-FBA1DA1CD580Q33814693-82392FE5-B709-40DE-8217-4C95B3ECCAC7Q33839485-1994EAA5-100A-48C6-8DC5-E48220680424Q33951963-035AC927-4B59-4BCA-AE40-825EB4FB7B43Q34357078-D870F601-4800-4782-A7AE-8B2BFE95DA7EQ34461554-F89627E3-4C48-4F2C-A6F6-E165767AEC38Q34545923-F28B58E8-2416-4BA3-BF7D-98FAE5391C49Q34637968-485C164D-222E-4007-8B36-0A28820FCD41Q34648342-00CA50E1-A003-4007-B71E-2E6F4738320BQ34754733-D5131D5A-575F-494D-AEC0-6C09A3774BF5Q34801630-6C8B88CC-DA08-4242-A2E0-792CB217AEE2Q34999724-2E637245-7B28-4D24-929B-4E25117F0E1AQ35105006-79E279FC-3CE4-4B17-B479-3B34B4177AF6Q35599288-1B6ED0FC-1A66-4F5E-85BA-A5A02F228B4FQ35644971-EF5E557F-F473-4D3B-9AC0-30421961B6E1Q35785244-5D7D6AF4-7F97-42ED-9EFF-ABAEDE051F09Q36565090-90432E16-C40E-4E3B-914C-42CA7D59729BQ37084521-75A18F2B-F97E-490D-BC03-9A11D5770BC4Q39594428-288F0765-3C15-4C87-A8E8-649E8D187043Q39594695-5C3DC211-5681-4DE3-AA50-A673EE8EF3C7Q39682713-EC5AF488-D010-423C-9256-8595E89BC0BEQ47566053-C2B08042-A592-4C31-8BC7-42EE8C5DD694
P2860
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@ast
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@en
type
label
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@ast
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@en
prefLabel
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@ast
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@en
P2093
P2860
P1433
P1476
Mutations in both gp120 and gp ...... ted at V3 and non-V3 epitopes.
@en
P2093
P2860
P304
P577
1998-09-01T00:00:00Z